Veradermics Reports Q3 2026 Financial Results and Positive Clinical Trial Data
Veradermics, Inc. (MANE) reported its third-quarter 2026 financial results, revealing a net loss of $21 million. This represents a slight increase in losses compared to the $20.1 million net loss recorded during the same period in 2025. Despite the widening net loss, the company highlighted significant clinical progress with positive results from its Study 302 Part B regarding VDPHL01. The announcement suggests a dual focus on managing operational costs while advancing its core product pipeline through key clinical milestones.
Tickers: $MANE